-
Kicking off fresh creative ventures through social media
Despite the significant health challenges I face as a person living with Duchenne muscular dystrophy, […]
-
ENTR-601-44 trial for DMD adults amenable to exon 44 skipping OK’d
The U.S. Food and Drug Administration (FDA) has given Entrada Therapeutics permission to launch a […]
-
How an emergency medical plan can benefit those of us with MD
“ICE” is a widely used acronym for “in case of emergency.” In today’s fast-paced world, […]
-
Entrada Therapeutics announces the FDA has removed the clinical hold on ENTR-601-44, their experimental therapeutic designed to skip exon 44
As an early funder of Entrada Therapeutics, we are pleased to share that the FDA […]
-
Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44
Entrada Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has lifted […]
-
Solid Biosciences Reports Positive Initial Clinical Data
Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003 Solid […]
-
Caregiving sometimes feels like walking a tightrope
My heart is walking a tightrope. I’m a 45-year-old wife to Jason and mother to […]
-
Life with Lily: Finding My Voice
Hello everyone! I’m so excited to launch my quarterly blog series as your 2025 National […]
-
2024 MDA Advocacy Collaboration Grantees are Working Towards Change
Advocacy for the neuromuscular disease community is just one of the key ways MDA works […]
-
MDA’s Origin Story: Grassroots Legacy
As we celebrate MDA’s 75th anniversary, you may be asking, how did this all begin? […]
